SEC62 and prostate cancer: In the following years, amplification and overexpression of the SEC62 gene was reported for various other cancer entities, including non-small cell lung cancer [318,320,328], thyroid cancer [318,320], hepatocellular cancer [322,340], ovarian cancer [325], breast cancer [325,334], head and neck squamous cell carcinoma [329,330], cervical cancer [336], vulvar cancer [335], atypical fibroxanthoma [339], and in larger prostate cancer patient cohorts [319].